| First Author | Spranger S | Year | 2017 |
| Journal | Cancer Cell | Volume | 31 |
| Issue | 5 | Pages | 711-723.e4 |
| PubMed ID | 28486109 | Mgi Jnum | J:242574 |
| Mgi Id | MGI:5905684 | Doi | 10.1016/j.ccell.2017.04.003 |
| Citation | Spranger S, et al. (2017) Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell 31(5):711-723.e4 |
| abstractText | Effector T cells have the capability of recognizing and killing cancer cells. However, whether tumors can become immune resistant through exclusion of effector T cells from the tumor microenvironment is not known. By using a tumor model resembling non-T cell-inflamed human tumors, we assessed whether adoptive T cell transfer might overcome failed spontaneous priming. Flow cytometric assays combined with intra-vital imaging indicated failed trafficking of effector T cells into tumors. Mechanistically, this was due to the absence of CXCL9/10, which we found to be produced by CD103+ dendritic cells (DCs) in T cell-inflamed tumors. Our data indicate that lack of CD103+ DCs within the tumor microenvironment dominantly resists the effector phase of an anti-tumor T cell response, contributing to immune escape. |
